Tag
Aurobindo Pharma Limited
3 articles
Aurobindo Pharma Completes Domestic Formulations Business Transfer
Aurobindo Pharma transfers its domestic branded generic formulations business to wholly-owned subsidiary Auropharm Limited.
The transfer was executed on a slump sale basis as a going concern, effectiv
Aurobindo Pharma USA Completes Lannett Acquisition
Aurobindo Pharma USA completes acquisition of Lannett Company following FTC approval on June 18, 2026.
Lannett becomes wholly owned subsidiary effective June 29, 2026, operating as Lannett Company LLC
Aurobindo Pharma Subsidiary Receives 2 US FDA Observations
Aurobindo Pharma discloses US FDA inspection at its wholly-owned API subsidiary Auroactive Pharma from June 22-26, 2026.
The inspection concluded with 2 observations, which the company will respond to